Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
9.62
+0.38 (4.11%)
Oct 8, 2025, 2:48 PM EDT - Market open
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 45 employees as of December 31, 2024. The number of employees decreased by 31 or -40.79% compared to the previous year.
Employees
45
Change (1Y)
-31
Growth (1Y)
-40.79%
Revenue / Employee
n/a
Profits / Employee
-$1,627,000
Market Cap
520.36M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45 | -31 | -40.79% |
Dec 31, 2023 | 76 | -13 | -14.61% |
Dec 31, 2022 | 89 | -15 | -14.42% |
Dec 31, 2021 | 104 | 31 | 42.47% |
Dec 31, 2020 | 73 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
FULC News
- 25 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fulcrum Therapeutics to Present at Upcoming Investor Meetings - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics to Present at Upcoming Medical Meetings - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Fulcrum Therapeutics to Participate in Upcoming May Conferences - GlobeNewsWire